Research work · 2013

Doxazosin

Ke Liu

Handbook of Metabolic Pathways of Xenobiotics

Abstract

Doxazosin is a selective α‐1‐adrenergic blocker. It is used to treat hypertension. [ 14 C‐2‐Quinazoline]‐doxazosin was administered via oral and intravenous dosing to mice, rats, dogs, and humans. In humans, urine and feces accounted for 9 and 63% of the administered radioactivity, respectively. Unmetabolized doxazosin accounted for 5% in feces. The majority of plasma radioactivity was the unchanged drug. Doxazosin was extensively metabolized. Major metabolic pathways were 6′‐ and 7′‐hydroxylations, and 6‐ and 7‐O‐demethylations. The 6‐ and 7‐O‐demethyl metabolites accounted for 16 and 7% of the oral dose and the 6′‐ and 7′‐hydroxy metabolites accounted for 5 and 7% of the dose, respectively. Minor products were 2‐piperazinyl metabolite, resulting from the cleavage of the amide linkage, and the 2‐amino compound, resulting from the opening of piperazine ring.

DOI: 10.1002/9781118541203.xen153